In the phase III DESTINY-Breast03 trial, T-DXd achieved an ORR of 79% compared to 35% with standard treatment in patients with unresectable or metastatic HER2-positive breast cancer previously treated with anti-HER2 regimens, leading to its FDA and EMA approval [52]. Here, ERBB2 is linked to breast carcinoma.